Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

All Drugs and Chemicals

Antineoplastic Agents

Immunomodulating Agents

Durvalumab

Antineoplastic Agents, Immunological

BA3011

BA3021

To be determined

Janet Dancey

Pierre-Olivier Gaudreau

John Moroney

Susan Ellard

Anna Tinker

Helen MacKay

Stephanie Lheureux

Diane Provencher

Susie K.S. Lau

This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.

This study is being conducted to determine if this approach is better or worse than the standard of care for ovarian cancer. The standard of care is defined as care most people get for ovarian cancer.

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Cancer Research Institute, New York City

AstraZeneca

BioAtla, Inc.

Canadian Cancer Trials Group

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer	NCT04918186	Ovarian Cancer	Durvalumab BA3011 BA3021 To be determine...	18 Years -	Canadian Cancer Trials Group
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer	NCT04918186	Ovarian Cancer	Durvalumab BA3011 BA3021 To be determine...	18 Years -	Canadian Cancer Trials Group

Spots Global Cancer Trial Database for ba3011

Every month we try and update this database with for ba3011 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ba3011

Every month we try and update this database with for ba3011 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ba3011 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.